# Single Dose Study of PF-06815345 in Healthy Subjects

> **NCT02654899** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 25 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** PF-06815345
- **OTHER:** Placebo
- **DRUG:** PF-06815345

## Key facts

- **NCT ID:** NCT02654899
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Trial discontinued on 04Apr2016 as a strategic business decision not to pursue the indication. Decision to terminate not due to safety or efficacy concerns.
- **Last updated:** 2018-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02654899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02654899, "Single Dose Study of PF-06815345 in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02654899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*